Research programme: erythropoietin gene expression inducers - Aventis/OSI
Latest Information Update: 30 Oct 1998
At a glance
- Originator Aventis; OSI Pharmaceuticals
- Class Small molecules
- Mechanism of Action Erythropoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 30 Oct 1998 Discontinued-Preclinical for Anaemia in USA (PO)
- 28 May 1998 Preclinical development for Anaemia in USA (PO)